Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

534
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
534
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: Design and implementation of a Targeted HealthcaRe InnoVation & Entrepreneurship (THRIVE) fellowship program.

PloS one·2026
Same author

Investigating PKD2 deficiency-associated cardiomyopathies using hESC-cardiomyocytes and bioengineered 3D ventricular cardiac tissue strips.

Cell death & disease·2026
Same author

Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction.

Heart failure reviews·2026
Same author

Design and implementation of a Targeted HealthcaRe InnoVation & Entrepreneurship (THRIVE) fellowship program.

PloS one·2025
Same author

Invasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2.

Nature communications·2025
Same author

Regenerative potential of mouse neonatal intervertebral disc depends on collagen crosslink density.

iScience·2024

相关实验视频

Updated: Jun 10, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.0K

使用机器学习进行增强的药物分类,并进行多重心脏收缩性检测.

Reza Aghavali1, Erin G Roberts1, Yosuke K Kurokawa1

  • 1Novoheart, Medera Inc., 6 Tide St., Boston, MA 02210, USA.

Pharmacological research
|October 13, 2024
PubMed
概括

来自人类干细胞的工程心脏组织改善了药物安全性测试. 这种新模型以86.2%的准确度预测药物心脏毒性,增强临床前药物开发和临床试验的成功.

关键词:
心脏收缩性是指心脏的收缩性.心脏组织工程心脏组织工程药物发现 药物发现电力生理学 电力生理学在体外查药物化合物的测试是药物化合物的测试.

更多相关视频

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

12.7K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K

相关实验视频

Last Updated: Jun 10, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.0K
Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening
10:39

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

12.7K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K

科学领域:

  • 生物医学工程 生物医学工程
  • 心血管药理学心血管药理学
  • 干细胞生物学 干细胞生物学

背景情况:

  • 药物诱导的心脏毒性是临床试验失败的主要原因之一.
  • 目前的临床前模型无法充分预测人类的心脏反应.
  • 人类多能干细胞衍生的心肌细胞为心脏安全性评估提供了一个有希望的替代方案.

研究的目的:

  • 开发和验证一种工程心脏组织模型,用于预测药物心脏毒性.
  • 创建一个强大的电子生理学和收缩性反应对已知的化合物的数据集.
  • 建立一个集成算法来分类未知的化合物的机械作用.

主要方法:

  • 使用了三种不同的工程心脏组织分析.
  • 组织暴露于5种机械学类化合物的度增加.
  • 开发了一个整体算法,整合了来自六个个别模型的数据.

主要成果:

  • 创建了关于心脏电生理学和收缩性的综合数据集.
  • 整体算法在分类复合机械作用时实现了86.2%的预测准确度.
  • 超越了单个试验模型的预测.

结论:

  • 工程心脏组织为人类心脏反应提供了更具预测性的临床前模型.
  • 整体算法提高了药物安全查的准确性.
  • 这种方法与监管方面的进步保持一致,例如FDA现代化法案2.0以提高药物开发成功率.